#USA #stock offering #Henderson #VolitionRx #epigenetics

VolitionRx Secures $1.2 Million Through Direct Offering

VolitionRx Limited, listed on the NYSE American under the symbol VNRX, has taken an important step towards expanding its operations and enhancing its innovative capabilities in the field of epigenetics. On August 4, 2025, the multinational company announced that it has entered into definitive agreements for a direct offering priced at $1.2 million. This move signifies Volition's commitment to advancing scientific breakthroughs and improving patient outcomes through early disease detection.

Details of the Offering

The direct offering encompasses the sale of 156,250 shares of common stock to specific directors and executive officers at a price of $0.64 per share. Additionally, the company will sell 1,734,375 shares, coupled with warrants that provide the option to purchase an equal number of shares. These stocks will be available at the same price of $0.64 per share and will target existing stockholders aimed at fostering further loyalty and investment in the company.

Warrant Details

The accompanying warrants have an exercise price of $0.768 per share, which investors can exercise immediately upon issuance. Expiration is slated for five years from the date of issuance, offering a considerable timeframe for potential profit and capital growth for investors. However, the insiders who acquire the 156,250 shares will not receive any warrants.

Financial Implications

Upon the anticipated closure of this offering on August 5, 2025, VolitionRx expects to net approximately $1.21 million. This amount is before the deduction of standard offering expenses and assumes no exercise of the provided warrants; however, the total gross proceeds could reach around $1.3 million if all warrants are exercised. The potential for increased funding will significantly enhance Volition’s capabilities in research, product development, and even strategic acquisitions.

Allocation of Funds

The proceeds from this offering are designated for critical areas such as furthering research, ongoing clinical trials, product commercialization efforts, and improving the company’s working capital. VolitionRx is boldly investing in its mission to utilize epigenetic science to create cutting-edge blood tests capable of identifying various diseases. This proactive approach to disease management reflects their goal of improving not only survival rates but also the quality of life of patients through earlier detection and monitoring.

About VolitionRx

Rooted in its pioneering spirit, VolitionRx concentrates on harnessing the power of epigenetics for real-world applications. The company is devoted to creating affordable and effective blood tests that facilitate the early detection of several diseases, encompassing certain cancer types and other serious conditions. Notably, VolitionRx operates extensively out of Belgium, with an innovation laboratory located in the U.S. and a significant office presence in London, signaling its international outreach and commitment to healthcare advancements.

The company’s unique focus on epigenetics not only aims to transform diagnostics but also seeks to provide tangible benefits to patients and medical professionals, thus promoting better health on a global scale.

In conclusion, VolitionRx's recent financing strategy through a $1.2 million direct offering allows the company to further its research efforts and solidifies its innovative position within the competitive biotechnology sector. Stakeholders remain hopeful as the company expands its horizons to address the pressing healthcare needs of today while positioning itself for future success in the realm of epigenetics.